• Users Online: 146
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
REVIEW ARTICLE
Year : 2017  |  Volume : 37  |  Issue : 4  |  Page : 121-129

Overview of clinical trials for dry age-related macular degeneration


1 Graduate Institute of Medical Sciences, National Defense Medical Center, Taoyuan, Taipei, Taiwan; School of Pharmacy, National Defense Medical Center, Taoyuan, Taipei, Taiwan, Republic of China
2 Department of Ophthalmology, Tri-Service General Hospital, National Defense Medical Center, Taoyuan, Taipei, Taiwan, Republic of China
3 School of Pharmacy, National Defense Medical Center, Taoyuan, Taipei, Taiwan; Genuine Chemical Pharmaceutical Co., Ltd, Taoyuan, Taipei, Taiwan, Republic of China
4 School of Pharmacy, National Defense Medical Center, Taoyuan, Taipei, Taiwan, Republic of China

Correspondence Address:
Charn-Jung Chang
School of Pharmacy, National Defense Medical Center, Taipei, Taiwan
Republic of China
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jmedsci.jmedsci_115_16

Rights and Permissions

The overall goal of treating age-related macular degeneration (AMD) is to target the underlying cause of the disease and prevent, or at least slow down, the loss of vision, which requires the preservation of the choroid, retinal pigment epithelium (RPE), and photoreceptors. At present, there is no proven drug treatment for dry AMD; however, the cessation of smoking and treatments based on the age-related eye diseases study vitamin formula combined with a healthy diet are considered the only options for slowing disease progression. A number of pharmaceutical agents are currently under evaluation for the treatment of dry AMD using strategies such as reduction RPE and photoreceptor loss, neuroprotection, visual cycle modulators, suppression of inflammation, prevention of oxidative damage, and choroidal perfusion enhancers. The hope is that some of these therapies will achieve significant improvement to current management and prevent future loss of vision in this devastating eye condition.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed175    
    Printed3    
    Emailed0    
    PDF Downloaded55    
    Comments [Add]    

Recommend this journal